{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-000537","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.754591+00:00","generated_at":"2026-05-24T06:15:47.135019+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Oncotelic announces successful Phase 1 of OT-101/IL-2 for solid tumors; plans combo studies with checkpoint inhibitors","bullets":["Phase 1 trial (NCT04862767) of OT-101 + IL-2 in advanced solid tumors shows tolerable safety, no unexpected signals.","Based on safety data, Oncotelic plans to advance OT-101 + IL-2 into studies with checkpoint inhibitors (e.g., PD-1 blockers) for lung, melanoma, colorectal cancers.","OT-101 is also in Phase 3 STOP-PC study for pancreatic cancer and has shown activity in gliomas.","CEO Dr. Vuong Trieu presented on TGFβ2's role in immune suppression at SWCR 2025 conference."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-000537","json":"https://secwatch.observer/filing/0001641172-25-000537.json","markdown":"https://secwatch.observer/filing/0001641172-25-000537.md","text":"https://secwatch.observer/filing/0001641172-25-000537.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000164117225000537/0001641172-25-000537-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000164117225000537/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:15:47.135019+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}